Literature DB >> 25866286

Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events.

Vincent Lo Re1,2,3, Dena M Carbonari2,3, Kimberly A Forde2,3,4, David Goldberg2,3,4, James D Lewis2,3,4, Kevin Haynes2,3, Kimberly B F Leidl2, Rajender K Reddy4, Jason Roy2,3, Daohang Sha2, Amy R Marks5, Jennifer L Schneider5, Brian L Strom2,3,6, Douglas A Corley5.   

Abstract

PURPOSE: Identification of acute liver failure (ALF) is important for post-marketing surveillance of medications, but the validity of using ICD-9 diagnoses and laboratory data to identify these events within electronic health records is unknown. We examined positive predictive values (PPVs) of hospital ICD-9 diagnoses and laboratory tests of liver dysfunction for identifying ALF within a large, community-based integrated care organization.
METHODS: We identified Kaiser Permanente Northern California health plan members (2004-2010) with a hospital diagnosis suggesting ALF (ICD-9 570, 572.2, 572.4, 572.8, 573.3, 573.8, or V42.7) plus an inpatient international normalized ratio ≥1.5 (off warfarin) and total bilirubin ≥5.0 mg/dL. Hospital records were reviewed by hepatologists to adjudicate ALF events. PPVs for confirmed outcomes were determined for individual ICD-9 diagnoses, diagnoses plus prescriptions for hepatic encephalopathy treatment, and combinations of diagnoses in the setting of coagulopathy and hyperbilirubinemia.
RESULTS: Among 669 members with no pre-existing liver disease, chart review confirmed ALF in 62 (9%). Despite the presence of co-existing coagulopathy and hyperbilirubinemia, individual ICD-9 diagnoses had low PPVs (range, 5-15%); requiring prescriptions for encephalopathy treatment did not increase PPVs of these diagnoses (range, 2-23%). Hospital diagnoses of other liver disorders (ICD-9 573.8) plus hepatic coma (ICD-9 572.2) had high PPV (67%; 95%CI, 9-99%) but only identified two (3%) ALF events.
CONCLUSIONS: Algorithms comprising relevant hospital diagnoses, laboratory evidence of liver dysfunction, and prescriptions for hepatic encephalopathy treatment had low PPVs for confirmed ALF events. Studies of ALF will need to rely on medical records to confirm this outcome.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  ICD-9 codes; acute liver failure; hepatotoxicity; liver injury; pharmacoepidemiology; validity

Mesh:

Year:  2015        PMID: 25866286      PMCID: PMC4509617          DOI: 10.1002/pds.3774

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  15 in total

Review 1.  Drug-induced hepatotoxicity.

Authors:  William M Lee
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

2.  AASLD position paper: the management of acute liver failure.

Authors:  Julie Polson; William M Lee
Journal:  Hepatology       Date:  2005-05       Impact factor: 17.425

3.  Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.

Authors:  George Ostapowicz; Robert J Fontana; Frank V Schiødt; Anne Larson; Timothy J Davern; Steven H B Han; Timothy M McCashland; A Obaid Shakil; J Eileen Hay; Linda Hynan; Jeffrey S Crippin; Andres T Blei; Grace Samuel; Joan Reisch; William M Lee
Journal:  Ann Intern Med       Date:  2002-12-17       Impact factor: 25.391

Review 4.  Treatment of hepatic encephalopathy.

Authors:  S M Riordan; R Williams
Journal:  N Engl J Med       Date:  1997-08-14       Impact factor: 91.245

5.  Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database.

Authors:  Vincent Lo Re; Kevin Haynes; David Goldberg; Kimberly A Forde; Dena M Carbonari; Kimberly B F Leidl; Sean Hennessy; K Rajender Reddy; Pamala A Pawloski; Gregory W Daniel; T Craig Cheetham; Aarthi Iyer; Kara O Coughlin; Sengwee Toh; Denise M Boudreau; Nandini Selvam; William O Cooper; Mano S Selvan; Jeffrey J VanWormer; Mark I Avigan; Monika Houstoun; Gwen L Zornberg; Judith A Racoosin; Azadeh Shoaibi
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-06-25       Impact factor: 2.890

Review 6.  Classification, etiology, and considerations of outcome in acute liver failure.

Authors:  R Williams
Journal:  Semin Liver Dis       Date:  1996-11       Impact factor: 6.115

7.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.

Authors:  Adrian Reuben; David G Koch; William M Lee
Journal:  Hepatology       Date:  2010-10-14       Impact factor: 17.425

8.  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.

Authors:  Naga Chalasani; Robert J Fontana; Herbert L Bonkovsky; Paul B Watkins; Timothy Davern; Jose Serrano; Hongqiu Yang; James Rochon
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

9.  A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents.

Authors:  K Arnold Chan; Alison Truman; Jerry H Gurwitz; Judith S Hurley; Brian Martinson; Richard Platt; James E Everhart; Richard H Moseley; Norah Terrault; Lynn Ackerson; Joe V Selby
Journal:  Arch Intern Med       Date:  2003-03-24

Review 10.  Acute liver failure in the United States.

Authors:  William M Lee
Journal:  Semin Liver Dis       Date:  2003-08       Impact factor: 6.115

View more
  8 in total

1.  Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model.

Authors:  Vincent Lo Re; Kevin Haynes; Kimberly A Forde; David S Goldberg; James D Lewis; Dena M Carbonari; Kimberly B F Leidl; K Rajender Reddy; Melissa S Nezamzadeh; Jason Roy; Daohang Sha; Amy R Marks; Jolanda De Boer; Jennifer L Schneider; Brian L Strom; Douglas A Corley
Journal:  Clin Gastroenterol Hepatol       Date:  2015-06-27       Impact factor: 11.382

2.  Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status.

Authors:  Vincent Lo Re; Dena M Carbonari; James D Lewis; Kimberly A Forde; David S Goldberg; K Rajender Reddy; Kevin Haynes; Jason A Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley
Journal:  Am J Med       Date:  2015-11-17       Impact factor: 4.965

3.  Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.

Authors:  Charitha Gowda; Craig W Newcomb; Qing Liu; Dena M Carbonari; James D Lewis; Kimberly A Forde; David S Goldberg; K Rajender Reddy; Jason A Roy; Amy R Marks; Jennifer L Schneider; Jay R Kostman; Janet P Tate; Joseph K Lim; Amy C Justice; Matthew Bidwell Goetz; Douglas A Corley; Vincent Lo Re
Journal:  Open Forum Infect Dis       Date:  2017-01-28       Impact factor: 3.835

4.  Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database.

Authors:  Sophie Billioti de Gage; Cédric Collin; Thien Le-Tri; Antoine Pariente; Bernard Bégaud; Hélène Verdoux; Rosemary Dray-Spira; Mahmoud Zureik
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

5.  Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources.

Authors:  Manel Pladevall-Vila; Anton Pottegård; Tania Schink; Johan Reutfors; Rosa Morros; Beatriz Poblador-Plou; Antje Timmer; Joan Forns; Maja Hellfritzsch; Tammo Reinders; David Hägg; Maria Giner-Soriano; Alexandra Prados-Torres; Miguel Cainzos-Achirica; Jesper Hallas; Lena Brandt; Jordi Cortés; Jaume Aguado; Gabriel Perlemuter; Bruno Falissard; Jordi Castellsagué; Emmanuelle Jacquot; Nicolas Deltour; Susana Perez-Gutthann
Journal:  CNS Drugs       Date:  2019-04       Impact factor: 5.749

6.  Analysis of weekend effect in severe acute liver injury: A nationwide database study.

Authors:  Albert Do; Ysabel C Ilagan-Ying; Tamar H Taddei
Journal:  Health Sci Rep       Date:  2019-11-22

7.  Trends in the epidemiology of inflammatory bowel disease in Colombia by demographics and region using a nationally representative claims database and characterization of inflammatory bowel disease phenotype in a case series of Colombian patients.

Authors:  Fabian Juliao-Baños; Joshua Kock; Mateo Arrubla; Omar Calixto; Joselyn Camargo; Lina Cruz; Juan Hurtado; Absalon Clavijo; Jorge Donado; Seth Schwartz; Maria T Abreu; Oriana M Damas
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

8.  Multiple bacterial infections increase the risk of hepatic encephalopathy in patients with cirrhosis.

Authors:  Lan-Ting Yuan; Seng-Kee Chuah; Shih-Cheng Yang; Chih-Ming Liang; Cheng-Kun Wu; Wei-Chen Tai; Tsung-Hsing Hung; Seng-Howe Nguang; Jiunn-Wei Wang; Kuo-Lun Tseng; Ming-Kun Ku; Pin-I Hsu; Deng-Chyang Wu; Chien-Ning Hsu
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.